- The stock price of TCR2 Therapeutics (Nasdaq: TCRR) increased by over 1% pre-market today. This is why it happened.
The stock price of TCR2 Therapeutics – a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors – increased by over 1% pre-market today. Investors responded positively to TCR2 Therapeutics unveiling new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.
TCR2 announced the completion of the 3-patient cohort at the new dose level 3.5A (3×108/m2 following lymphodepletion) using a split dosing approach. And two patients were evaluable for safety. In both cases, gavo-cel was well-tolerated with no patients experiencing on-target, off tumors toxicities or Grade ≥3 cytokine release syndrome (CRS) non-hematologic toxicities.
TCR2 anticipates the identification of the RP2D in 4Q21.
TCR2 announced today that, in alignment with its pipeline prioritization on solid tumors, the Company has deprioritized the development of TC-110 for the treatment of patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia and plans instead to evaluate business development options.
TCR2 announced today the company anticipates the IND filing for its first TRuC-T cell enhanced with a PD1xCD28 switch receptor to be in 1Q22.
TCR2 announced the selection of its lead candidate targeting CD70 co-expressing an IL-15 enhancement as TC-520. And in new preclinical data highlighted at the R&D Day, TC-520 enhanced with membrane-bound IL-15 resulted in a significant increase in TC-520 cells with a CD8+ naïve/T memory stem cells phenotyope, improved autonomous persistence as well as increased expansion following repeated stimulation with CD70-expressing cancer cell lines.
The company anticipates initiating IND-enabling studies for TC-520 with an indication focus on renal cell carcinoma in 2022.
TCR2 announced new preclinical data demonstrating allogeneic (off-the-shelf) TRuC-T cells targeting mesothelin that utilized a CRISPR/Cas9 endonucleases approach and the use of fully human TCRγ/δ domains reduced the risk of immunogenicity and host rejection, lacked alloreactivity while maintaining clearance of tumor cells compared to autologous TRuC-T cells targeting mesothelin.
TCR2 is currently evaluating the combination of enhancements with allogeneic TRuC-T cells to potentially improve persistence.
And the company anticipates the identification of a lead candidate for its allogeneic program in 2022.
TCR2 announced new preclinical data demonstrating proof-of-concept for TRuC Treg cells targeting HLA-A*02 for the prevention of Graft versus Host Disease (GvHD). In in vitro and in vivo experiments, TRuC Tregs utilizing the full TCR signaling complex promoted and stabilized Tregs by suppressing the proliferation of mismatched effector cells and inhibiting the production of cytokines in a dose-dependent manner.
TCR2 is planning to evaluate business development options to enable the treatment of patients with GvHD and other autoimmune diseases.
“At TCR2, our mission is to build the next great cell therapy company in solid tumors based on the early success of our mesothelin franchise and an emerging pipeline which will extend our reach into new cancer patient populations and beyond,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. “Today we will review our narrowed focus on solid tumors and unveil new strategies to potentially further enhance the persistence and efficacy of our TRuC-T cells. In addition, we will introduce compelling preclinical data for our TRuC Tregs, which could expand our footprint into the autoimmune disease setting. We believe that TCR2 is already helping to change the treatment paradigm for patients with treatment-refractory solid tumors and, through continued innovation, will progress our re-prioritized pipeline to patients with a variety of unmet medical needs.”
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.